Core Viewpoint - Plus Therapeutics, Inc. has announced a reverse stock split at a ratio of 1-for-25 to comply with Nasdaq's minimum bid price requirement of $1.00 for continued listing [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 2, 2026, reducing the outstanding common stock from approximately 171,550,698 shares to about 6,862,027 shares [1][3]. - Every 25 shares of Plus Therapeutics common stock will be combined into one share, with no change to the par value of $0.001 per share [3]. - Holders of fractional shares will receive a cash payment instead of fractional shares, and the shares underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly [3]. Group 2: Stockholder Instructions - The Company has retained Broadridge Financial Services, Inc. as the exchange agent for the reverse stock split, providing instructions for stockholders with shares in certificate form [4]. - Stockholders holding shares in book-entry form or brokerage accounts will see the impact of the reverse stock split reflected in their accounts without needing to take action [4]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, aiming to enhance clinical outcomes [5]. - The Company is advancing a pipeline of product candidates, particularly in leptomeningeal metastases and recurrent glioblastoma, supported by strategic partnerships for development and manufacturing [5].

Core Insights - Eli Lilly has agreed to acquire Centessa Pharmaceuticals for an initial $6.3 billion, enhancing its neuroscience portfolio and capabilities in sleep medicine [1] Company Summary - The acquisition of Centessa Pharmaceuticals represents a strategic move for Eli Lilly to expand its offerings in the neuroscience sector [1] - The deal is expected to bolster Eli Lilly's research and development capabilities in sleep-related treatments [1] Industry Summary - This acquisition highlights the growing interest and investment in the neuroscience and sleep medicine markets, indicating potential growth opportunities within these sectors [1]

Core Insights - The impact of artificial intelligence (AI) on various sectors is significant, but many CEOs (56%) do not see substantial benefits from their AI investments [1] - The healthcare sector presents a unique opportunity for AI to improve outcomes and efficiency [2] Company Insights - Recursion Pharmaceuticals is leveraging AI to transform drug development, significantly reducing the time and cost associated with bringing new drugs to market [6] - The average cost to develop a drug is estimated between $900 million and $2 billion, with a high failure rate of 90% for drugs entering clinical trials [5] - Recursion's AI platform utilizes over 50 petabytes of data to help pharmaceutical companies identify promising drug candidates, thereby optimizing their R&D efforts [7] - The company is collaborating with established pharmaceutical firms like Sanofi and Roche to enhance drug development processes [8] - Recursion's revenue model is currently based on partnerships with drugmakers, with expectations for significant revenue growth in the upcoming fiscal year as developmental milestone payments increase [9] - The AI-powered drug development market is projected to grow at an average rate of 30% per year through 2035, indicating a robust future for companies like Recursion Pharmaceuticals [9]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and improvements in net loss for the fiscal year 2025, driven by increased sales and strategic partnerships [5][4]. Financial Highlights - FY 2025 net product revenues increased by 65% to $1.005 million, up from $607.6 thousand in 2024, attributed to rising sales, price increases, and fewer returns [5]. - Gross profit for 2025 was approximately $223.8 thousand, slightly up from $222.8 thousand in 2024, despite inventory write-offs related to short-dated products [5]. - Operating expenses decreased to approximately $8.4 million in 2025 from $10.0 million in 2024, with a notable reduction in R&D costs [5]. - Net loss attributable to common shareholders improved to approximately $7.37 million, or $11.73 per share, compared to a net loss of approximately $7.96 million, or $74.17 per share, in 2024 [5]. Recent Business Highlights - In March 2026, the company announced successful outcomes in its expanded access study for relapsing babesiosis, leading to calls for revised treatment guidelines [5]. - A partnership with GoodRx was established in February 2026 to offer savings on ARAKODA®, expanding its sales footprint to over 70,000 pharmacies [5]. - The company exercised its Florida State University license option for large-scale purification of castanospermine in January 2026, indicating readiness to begin regulatory processes for Australian Chestnut Extract [5]. - A Phase 2 B-FREE Chronic Babesiosis Study commenced in November 2025, aiming to enroll up to 100 patients [5]. - A sponsored research agreement with Tulane University was signed in July 2025 to evaluate tafenoquine's activity against Lyme and Bartonella bacteria [5].

Core Insights - Biomea Fusion has initiated Phase II clinical trials, COVALENT-211 and COVALENT-212, to evaluate icovamenib in type 2 diabetes patients who are insulin-deficient or inadequately controlled on GLP-1 receptor agonist therapy [1][2][3] Study Details - COVALENT-211 targets adult patients with insulin-deficient type 2 diabetes who are not achieving glycemic targets despite being on one to three antihyperglycemic medications [3] - COVALENT-212 focuses on adult patients with type 2 diabetes inadequately controlled on GLP-1 receptor agonist therapy, allowing for additional background therapies [4] - Each study plans to enroll approximately 60 participants, with a 2:1 randomization of icovamenib to placebo, and will assess glycemic control over a 12-week treatment period followed by a 40-week off-treatment period [5][6] Expected Outcomes - Topline data from both studies is anticipated in the fourth quarter of 2026, aiming to evaluate icovamenib's potential to restore beta-cell function in high-need populations [6][8] Mechanism of Action - Icovamenib is an investigational small molecule that targets menin, a transcriptional regulator involved in beta-cell dysfunction, potentially restoring insulin secretion and glycemic control [9][10] Market Context - Type 2 diabetes affects over 38 million Americans, with a significant portion of patients not achieving glycemic control on current therapies, highlighting a substantial unmet medical need [11]

Core Insights - TNX-4800 is a long-acting monoclonal antibody in development as a single-dose prophylactic for Lyme disease, demonstrating safety and pharmacokinetics supportive of approximately four months of protection [1][2][3] Phase 1 Study Results - The Phase 1 study evaluated the safety and tolerability of TNX-4800 in 44 healthy subjects aged 19-65, with 41 completing the study [4][10] - No significant safety signals were observed, with most adverse events being mild or moderate [5][12] - Peak serum concentration increased by approximately 25-fold for a 20-times increase in dose, with serum TNX-4800 measurable at two days and remaining quantifiable for over 200 days in 80% of subjects at the lowest dose [5][12] Mechanism and Advantages - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, which causes 99.9% of Lyme disease cases in the U.S. [2][9] - The antibody provides passive immunity by directly supplying neutralizing antibodies, bypassing the need for a vaccine to induce the immune system [4][9] - Unlike existing vaccines that require complex immunization schedules and take over six months to provide protection, TNX-4800 offers immunity within two days with a single subcutaneous dose [3][9] Future Study Plans - The company plans to initiate a randomized, double-blind, placebo-controlled adaptive Phase 2 field study in the first half of 2027, pending FDA clearance [1][6] - The primary endpoint will be the prevention of Lyme disease at four months, with a key secondary endpoint at six months [6][11] Product Development and Background - TNX-4800 was in-licensed from UMass Chan Medical School in 2025 and is designed to maintain protective antibody levels for approximately four months [2][9] - The company expects to have GMP investigational product available for clinical testing in early 2027 [7]

Core Insights - Bausch Health Companies Inc. will announce its first quarter 2026 financial results on April 29, 2026, after market close [1] - A live conference call and webcast will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update [1][2] Company Overview - Bausch Health is a global diversified pharmaceutical company focused on improving healthcare outcomes through a range of products in various fields including gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health [2] - The company aims to be a globally integrated healthcare provider, trusted by patients, healthcare professionals, employees, and investors [2]

Core Insights - Novo Nordisk has significantly reduced the prices of its diabetes and weight-loss medications, Ozempic and Wegovy, by up to 36% and 48% respectively in India to enhance competitiveness against local generics entering the market [1] Pricing Strategy - The price cuts are a strategic move by Novo Nordisk to maintain market share as local drug manufacturers introduce lower-cost generic alternatives [1] Market Context - The decision comes amid increasing competition in the Indian pharmaceutical market, where generics are becoming more prevalent, prompting established companies to adjust their pricing strategies [1]

Core Viewpoint - Eli Lilly and Company is set to acquire Centessa Pharmaceuticals to enhance its neuroscience portfolio, particularly in sleep medicine, focusing on treatments for sleep-wake disorders [1][2]. Group 1: Acquisition Details - Lilly will acquire all issued and to be issued share capital of Centessa for $38.00 in cash per share, plus a contingent value right (CVR) that could add up to $9.00 based on milestone achievements, totaling a potential aggregate of $47.00 per share [3][4]. - The total equity value of the transaction is approximately $6.3 billion, with the CVR representing an additional potential value of about $1.5 billion [4][6]. - The transaction is expected to close in the third quarter of 2026, pending approval from Centessa shareholders and regulatory bodies [5][6]. Group 2: Strategic Implications - Centessa's lead candidate, cleminorexton, has shown a promising profile in Phase 2a studies for narcolepsy and other sleep disorders, which aligns with Lilly's strategic focus on neuroscience [2][3]. - The acquisition will allow Lilly to leverage Centessa's expertise in orexin receptor biology, which is crucial for addressing sleep-wake cycle disorders [3][4]. - The collaboration aims to accelerate the development of orexin-based therapeutics across various neurological conditions, enhancing patient outcomes [3][4]. Group 3: Support and Approval - Entities affiliated with Medicxi Ventures, Index Ventures, and General Atlantic have signed agreements to support the transaction, representing approximately 24.1% of Centessa's outstanding shares [7]. - Both companies' boards have approved the transaction, indicating strong internal support for the acquisition [6][7].

Core Insights - Fennec Pharmaceuticals announced the grant of incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan, totaling 377,500 shares [1][2] Group 1: Stock Options and Inducement Plan - The incentive stock options (ISOs) have an exercise price of $5.77 per share, equal to the closing price on March 30, 2026, and a term of ten years from the grant date [3] - One-third of the shares underlying each ISO will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following 24 months, contingent on continued employment [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its primary product being PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity [4] - PEDMARK received FDA approval in September 2022, followed by European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI [4] - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [5]